Kinase Inhibitors and Atrial Fibrillation: Mechanisms of Action and Clinical Implications.

Autor:	Potter AS; Division of Cardiology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA; Davis Heart and Lung Research Institute, The Ohio State University, Columbus, Ohio, USA., Hulsurkar MM; Cardiovascular Research Institute, Baylor College of Medicine, Houston, Texas, USA; Department of Integrative Physiology, Baylor College of Medicine, Houston, Texas, USA., Wu L; Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, Alabama, USA., Narasimhan B; Department of Cardiology, Houston Methodist Hospital, Houston, Texas, USA., Karimzad K; Department of Cardiology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Koutroumpakis E; Department of Cardiology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Palaskas N; Department of Cardiology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Deswal A; Department of Cardiology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Kantharia BK; Cardiovascular and Heart Rhythm Consultants & Icahn School of Medicine at Mount Sinai, New York, New York, USA., Wehrens XHT; Cardiovascular Research Institute, Baylor College of Medicine, Houston, Texas, USA; Department of Integrative Physiology, Baylor College of Medicine, Houston, Texas, USA; Department of Medicine (in Cardiology), Baylor College of Medicine, Houston, Texas, USA; Department of Neuroscience, Baylor College of Medicine, Houston, Texas, USA; Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA; Center for Space Medicine, Baylor College of Medicine, Houston, Texas, USA. Electronic address: wehrens@bcm.edu.
Jazyk:	angličtina
Zdroj:	JACC. Clinical electrophysiology [JACC Clin Electrophysiol] 2023 Apr; Vol. 9 (4), pp. 591-602. Date of Electronic Publication: 2023 Feb 22.
DOI:	10.1016/j.jacep.2022.11.034
Abstrakt:	Recent advances have significantly expanded the options of available therapeutics for cancer treatment, including novel targeted cancer therapies. Within this broad category of targeted therapies is the class of kinase inhibitors (KIs), which target kinases that have undergone aberrant activation in cancerous cells. Although KIs have shown a benefit in treating various forms of malignancy, they have also been shown to cause a wide array of cardiovascular toxicities, with cardiac arrhythmias, in particular atrial fibrillation (AF), being 1 of the predominant side effects. The occurrence of AF in patients undergoing cancer treatment can complicate the treatment approach and poses unique clinical challenges. The association of KIs and AF has led to new research aimed at trying to elucidate the underlying mechanisms. Furthermore, there are unique considerations to treating KI-induced AF because of the anticoagulant properties of some KIs as well as drug-drug interactions with KIs and some cardiovascular medications. Here, we review the current literature pertaining to KI-induced AF. Competing Interests: Funding Support and Author Disclosures Dr Deswal is supported in part by the Ting Tsung and Wei Fong Chao Distinguished Chair. Dr Wehrens is supported by NIH grants R01- HL089598, R01-HL147108, and R01-HL153350, and the Juanita P. Quigley Endowed Chair in Cardiology. Dr Hulsukar is funded by a career development award by the AHA. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. (Copyright © 2023 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu